312 related articles for article (PubMed ID: 25164070)
1. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
4. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
[TBL] [Abstract][Full Text] [Related]
6. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
[TBL] [Abstract][Full Text] [Related]
9. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
[TBL] [Abstract][Full Text] [Related]
12. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
13. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
Yeon A; You S; Kim M; Gupta A; Park MH; Weisenberger DJ; Liang G; Kim J
Theranostics; 2018; 8(16):4520-4534. PubMed ID: 30214636
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Beddowes E; Spicer J; Chan PY; Khadeir R; Corbacho JG; Repana D; Steele JP; Schmid P; Szyszko T; Cook G; Diaz M; Feng X; Johnston A; Thomson J; Sheaff M; Wu BW; Bomalaski J; Pacey S; Szlosarek PW
J Clin Oncol; 2017 Jun; 35(16):1778-1785. PubMed ID: 28388291
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
16. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
17. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
18. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
19. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
[TBL] [Abstract][Full Text] [Related]
20. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
